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Background: There has been increasing recognition of adverse neurodevelopmental
sequelae in some children after repair of congenital heart defects. Even among
children with the same cardiac defect, significant interindividual variation exists in
developmental outcome. Polymorphisms of apolipoprotein E have been identified as
a risk factor for worse neurologic recovery after central nervous system injury.
Methods: A single-institution prospective study of patients 6 months of age
undergoing cardiopulmonary bypass for repair of congenital heart defects was
undertaken to evaluate the association between apolipoprotein E genotype and
postoperative neurodevelopmental dysfunction. Developmental outcomes were
evaluated at 1 year of age by using the Bayley Scales of Infant Development.
Results: One-year evaluation was performed in 244 patients. After adjustment for
preoperative and postoperative covariates—including gestational age, age at oper-
ation, sex, race, socioeconomic status, cardiac defect, and use of deep hypothermic
circulatory arrest—the apolipoprotein E 2 allele was associated with a worse
neurologic outcome as assessed by the Psychomotor Developmental Index of the
Bayley Scales of Infant Development (P  .036). Patients with the apolipoprotein
E 2 allele had approximately a 7-point decrease in the Psychomotor Developmental
Index.
Conclusions: Apolipoprotein E 2 allele carriers had significantly lower Psychomo-
tor Development Index scores at 1 year of age after infant cardiac surgery. The
effect was independent of ethnicity, socioeconomic status, cardiac defect, and use of
deep hypothermic circulatory arrest. An effect of the apolipoprotein E 4 allele was
not detected. Genetic polymorphisms that decrease neuroresiliency and impair
neuronal repair after central nervous system injury are important risk factors for
neurodevelopmental dysfunction after infant cardiac surgery.
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Adramatic reduction in mortality after sur-gical correction of congenital heart de-fects (CHD) in recent years has been ac-companied by increasing recognition ofadverse neurodevelopmental sequelae insome survivors.1-3 Evaluation of children
after neonatal repair of CHD demonstrates a pattern of
neurodevelopmental sequelae characterized by cognitive
impairment, speech and language abnormalities, impaired
visuospatial and visuomotor skills, attention deficit hyper-
activity disorder, motor delays, and learning disabilities.4-6
Cerebral ischemia in the perioperative period has been
proposed to be a primary mechanism of central nervous
system (CNS) injury. Management strategies during the
operation—including type of support (deep hypothermic
circulatory arrest [DHCA] or continuous cardiopulmonary
bypass [CPB]), hemodilution, degree of cooling, and blood
gas management—have been implicated as factors in post-
operative neurodevelopmental dysfunction.1-8 These poten-
tial risk factors do not fully explain the frequency or pattern
of neurodevelopmental dysfunction. There is significant in-
terindividual variation in developmental outcome, even
among children with the same cardiac defect, suggesting
that other patient-specific factors may be important deter-
minants of CNS injury.
The role of genetic polymorphisms that increase suscep-
tibility to neurologic injury has not been explored in chil-
dren with CHD. Apolipoprotein E (APOE) is an important
regulator of cholesterol metabolism.9-12 APOE-containing
lipoproteins are the primary lipid transport vehicles in the
CNS. There is increasing evidence that APOE is important
for neuronal repair.9,11-15 There are 3 common isoforms of
APOE (E2, E3, and E4), which are encoded by 3 alleles (2,
3, and 4, respectively) and vary by single amino acid
substitutions. A strong association has been validated be-
tween the APOE 4 allele and Alzheimer’s disease.10 The
APOE genotype has been shown to have an important role
as a determinant of neurologic recovery after CNS ischemia,
intracerebral hemorrhage, and traumatic brain injury.13-17
There is evidence of an association of APOE genotype with
neurocognitive decline after cardiac surgery in adults.18-20
We evaluated the association between postoperative neuro-
logic dysfunction and APOE genotype in infants undergoing
cardiac surgery.
Methods
Patient Population
The Institutional Review Board at The Children’s Hospital of
Philadelphia approved the study. Patients 6 months of age or less
undergoing CPB, with or without DHCA, for repair of CHD were
eligible. Exclusion criteria included (1) multiple congenital anom-
alies, (2) recognizable genetic or phenotypic syndrome other than
chromosome 22q11 microdeletions, and (3) language other than
English spoken in the home.
Informed consent was obtained from the parent or guardian.
Operations were performed by 4 cardiac surgeons with a dedicated
team of cardiac anesthesiologists. Alpha-stat blood gas manage-
ment was used. DHCA was used at the surgeon’s discretion. The
mean hematocrit after institution of CPB and hemodilution was
26% 3.5%. Before DHCA, patients underwent core cooling with
topical hypothermia to a nasopharyngeal temperature of 18°C.
Modified ultrafiltration was performed in all patients.
APOE Genotype Determination
Whole blood was obtained before the operation and stored at 4°C.
Genomic DNA was prepared and used to determine APOE geno-
types by using a previously published method.18,21
One-Year Neurodevelopmental Examination
Children were evaluated at 12 months of age, corrected for pre-
maturity, plus or minus 2 weeks. All study personnel were blinded
to the genotype. Socioeconomic status (SES) and ethnicity were
determined by parental reporting. Developmental assessment in-
cluded the Bayley Scales of Infant Development, which yielded 2
scores: the Psychomotor Development Index (PDI) and the Mental
Developmental Index (MDI). The MDI assesses memory, problem
solving, early number concepts, generalization, vocalizations, and
language and social skills. The PDI assesses control of gross
muscle function, including crawling and walking, as well as fine
muscle skills necessary for prehension, use of writing instruments,
and imitation of hand movements. Both the MDI and PDI are
normalized to a mean of 100 with an SD of 15. They yield an
accurate assessment of the child’s developmental status at 1 year
but are not predictors of later outcome, such as IQ in adolescence.
The evaluation also included medical history, growth measure-
ments, and detailed neurologic examination assessing active and
passive tone, reflexes, gross motor skills, and visual and auditory
responses. Patients were evaluated by a genetic dysmorphologist.
Because recognition of genetic syndromes in neonates may be
difficult, some children with genetic abnormalities had been en-
rolled as infants. Chromosome analysis and testing for microdele-
tions of chromosome 22q11 were performed as indicated.
Data Analysis
Patients were grouped according to cardiac diagnosis: group 1
consisted of patients with hypoplastic left heart syndrome (HLHS);
group 2 consisted of patients with conotruncal defects (tetralogy of
Fallot, transposition of the great arteries, truncus arteriosus, and so
on); and all other defects were coded as group 3. Patients were
additionally coded according to a previously described classifica-
tion incorporating anatomy and perioperative physiology that has
been shown to be predictive of perioperative mortality.22 Class I is
2 ventricles with no aortic arch obstruction, class II is 2 ventricles
with aortic arch obstruction, class III is single ventricle with no
arch obstruction, and class IV is single ventricle with arch obstruc-
tion. Patients with tetralogy of Fallot and transposition of the great
arteries are in class I, whereas patients with HLHS or variants are
in class IV. Results of the genetic evaluations were classified as
normal if no genetic or chromosomal abnormality was demon-
strated, abnormal if a specific diagnosis was confirmed, and sus-
pect if there was evidence of a genetic syndrome that could not be
confirmed. Results of the neurologic examinations were classified
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as normal if no abnormalities or only mild abnormalities that did
not affect motor skills were found, suspect when there was a
moderate degree of abnormality (ie, moderate hypotonia with
generally normal reflexes and mildly abnormal motor skills), and
abnormal whenever significant abnormalities of tone, reflexes, or
motor skills were present.
Statistical Analysis
The primary outcome was the PDI, chosen on the basis of the
Boston Circulatory Arrest Study finding that use of DHCA was
associated with a significant decrease in the PDI.2 Secondary
measures of neurologic outcome included the MDI, head circum-
ference at 1 year, and neuromuscular examination. The primary
predictor of interest was APOE genotype. Subjects were grouped
into the 2 group (22 and 32), the 33 group, and the 4
group (34 and 44). There were no 22 patients in the study
population. Five 24 subjects were excluded from the analyses
because the effects of the 2 and 4 alleles are opposing in
Alzheimer’s disease. Twelve subjects with a missing APOE geno-
type were also excluded. Because PDI was selected as the primary
outcome, we did not make multiple comparison adjustments for
analyses of the additional correlated outcomes. Baseline evaluation
of APOE genotype effects used analysis of variance with 2 degrees
of freedom (df), and further investigation of the APOE effects after
covariate adjustment focused on separate comparisons of the 2
group versus the 33 group and the 4 group versus the 33
group.
Linear regression was used to characterize the crude and ad-
justed association between the 1-year outcomes PDI, MDI, and
head circumference. Logistic regression was used for the categor-
ical neuromuscular examination outcome. Suspect and abnormal
neuromuscular examination groups were pooled to form a “not
normal” group and thus derive a binary response variable. Three
regressions were performed for each outcome. First, the marginal
association between genotype and outcome was considered with-
out adjustment for any covariates. Next, the preoperative adjusted
regressions included preoperative characteristics of race (white,
black, or other), sex, SES, gestational age, birth weight, head
circumference percentiles, diagnostic group, and suspected or def-
inite genetic disorder. Apgar scores were not significantly associ-
ated with outcome, and estimates of genotype effect did not
substantially change with or without adjustment for Apgar score.
Because 11 children were missing Apgar data, Apgar scores were
dropped from the regression model rather than imputing the scores
or dropping those cases. Missing percentiles of birth weight (n 
2) and head circumferences at birth (n  24) were imputed by
using the percentile at the 1-year follow-up examination. Subjects
missing birth head circumference measurements were dropped
from the analysis of 1-year head circumference. Finally, the pre-
operative and postoperative adjusted regression included these
variables plus variables related to the cardiac repair. Operative
variables included class (I-IV), operation, age and weight at oper-
ation, hematocrit on CPB, total support time (duration of CPB plus
DHCA), number of bypass runs, and use of DHCA. The relation-
ship between APOE genotype group and all covariates was ex-
plored by analysis of variance for quantitative traits and by 2
analysis for categorical traits.
Interaction between genotype and major preoperative or post-
operative covariates was tested by including interaction terms in
the preoperative and postoperative adjusted regression analysis.
Because the power to detect genotype by covariate interactions
was expected to be low, fitted genotype effects for patient subsets
were examined to determine whether the same general trends were
manifested. Specifically, the signs of coefficients for the APOE
effects were examined in subgroups on the basis of presence of a
suspected or definite genetic disorder, males versus females, Cau-
casian children, SES, diagnostic group, support time, and use of
DHCA.
Results
Between October 1, 1998, and September 20, 2001, 467
eligible patients underwent cardiac surgery (Table 1).
Twenty patients died before enrollment. A total of 368
patients (82%) were enrolled. Thirteen patients (3.5%) died
during the initial hospitalization, and 15 additional patients
(4.1%) died after hospital discharge before 1 year of age.
There were 340 potential patients for the 1-year evaluation,
and 244 (72%) returned. The study population consisted of
244 patients in whom the 1-year evaluation was completed
by September 20, 2002. Two additional premature infants
born before September 20, 2001, underwent evaluation in
October 2002 and are not included in the study population.
There was a trend toward a lower return rate among black
infants and those with more complex heart defects (class
IV). However, the primary reason for not returning was
geographic location, because no travel funds were available.
There was no difference in APOE genotype between return-
ing and nonreturning patients.
On the Bayley scales, the mean PDI score was 77.0 
18.0, and the mean MDI score was 88.6  15.5. The MDI
was 70 in 28 patients (11%), and the PDI was 70 in 80
patients (33%). The neuromuscular examination had abnor-
mal or suspect results in 96 patients (39%), with hypotonia
in 85; hypertonia in 5; mixed tonal abnormalities in 3; and
asymmetry, spastic quadriplegia, and hyperreflexia in 1
each. Head circumference at 1 year was at or below the fifth
percentile in 60 patients (25%). Genetic examination results
were normal in 175 patients, a definite genetic abnormality
was present in 29 (12%; including 13 with 22q11 microde-
letions), and 40 patients were classified as having suspect
results.
No demographic or preoperative characteristics were sig-
nificantly related to APOE genotype (Table 2). Although the
test for differences of APOE distribution between male and
female infants was not significant (P  .130), there was a
trend for a deficit of 4-containing genotypes in males.
Allele frequencies in Caucasian males in this sample were
2, 0.081; 3, 0.812; and 4, 0.108; for Caucasian females,
they were 2, 0.075; 3, 0.769; and 4, 0.157. Allele fre-
quencies in Caucasian subjects are expected to be 0.085 for
2, 0.768 for 3, and 0.147 for 4. The APOE genotype
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distribution did not significantly differ from Hardy-Wein-
berg proportions.21 APOE genotype frequencies are ex-
pected to vary by race.22-25 Although this variation was not
statistically significant, the expected deficit of 4 alleles in
Asians was seen. The distribution of male and female sub-
jects did not differ significantly by race (P  .17; data not
shown). Operative variables for the first operation and for
the entire first year of life are shown in Tables 3 and 4,
respectively. None was related to APOE genotype (all P 
.2).
The neurologic outcomes, stratified by APOE genotype,
are shown in Table 5 and are shown for the Caucasian
subgroup in Table 6. All other analyses use all races. Re-
gression analyses unadjusted for any covariates showed a
significant APOE effect for PDI (P  .016; 2 df) and
neuromuscular examination (P  .032; 2 df; Figure 1). In
TABLE 1. Characteristics of the patient population
Variable
Returned
(n  244)*
Did not return
(n  94)
Hospital death
(n  13)
Late death
(n  15)
No. % No. % No. % No. %
Race
Asian/Pacific Islander, Hispanic,
Native American, other
42 17 21 22 4 31 1 7
Black, not Hispanic 31 13 29 31 3 23 3 20
White, not hispanic 171 70 44 47 6 46 11 73
Sex
Female 145 59 58 62 8 62 8 53
Male 99 41 36 38 5 38 7 47
APOE genotype
22 0 2 2.1 0 0
23 28 11.5 11 11.7 2 15.4 1 6.7
24 5 2.0 4 4.3 1 7.6 0
33 147 60.2 53 56.4 6 46.2 8 53.3
34 48 19.7 16 17.0 2 15.4 4 46.7
44 4 1.7 1 1.1 0 0
Not done 12 4.9 7 7.4 2 15.4 2 13.3
Gestational age (wk)
Mean  SD 38.5 2.1 38.5 1.8 36.8 2.6 37.1 4.4
n 242 80 9 14
Birth weight (g)
Mean  SD 3172 634 3124 573 2752 459 2680 793
n 243 83 11 14
Birth head circumference (%)
Mean  SD 43 31 38 29 37 31 42 36
n 231 77 7 14
Apgar at 1 min
Mean  SD 7.8 1.6 7.9 1.3 7.0 1.7 7.51 1.5
n 233 81 10 14
Apgar at 5 min
Mean  SD 8.6 0.9 8.8 0.6 8.4 1.0 8.4 0.8
n 233 81 10 14
Diagnostic group
HLHS 35 14.3 18 19.1 6 46.2 7 46.6
Conotruncal defects 135 55.3 54 57.4 2 15.4 4 26.7
Other defects 74 30.4 22 23.5 5 35.4 4 26.7
Operative class
Two ventricles: no arch obstruction 143 58.6 43 45.7 3 23.1 3 20.0
Two ventricles: arch obstruction 21 8.6 14 14.9 1 7.7 1 6.7
Single ventricle: no arch obstruction 29 11.9 5 5.3 1 7.7 3 20.0
Single ventricle: arch obstruction 51 20.9 32 34.1 8 61.5 8 53.3
Age at first operation (d)
Mean  SD 43 5.4 53 6.3 29 4.7 39 5.9
Median (range) 7 (1-186) 14 (1-188) 6 (1-126) 6 (1-178)
Weight at first operation, kg (mean  SD) 3.96 1.32 3.93 1.26 2.99 0.93 3.35 1.02
*Two premature infants born before September 20, 2001, were scheduled for evaluation in October 2002.
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each case, infants in the APOE 2 group performed less well
than those with the reference 33 genotype. Comparing the
2 group with the other groups pooled gave P values of
.006, .041, .041, and .27 for PDI, MDI, neuromuscular
examination, and head circumference, respectively (Table
7).
The APOE 2 effect on PDI remained significant after
adjusting for the preoperative (P  .023) or preoperative
and postoperative (P  .036) covariates (Table 7). After
adjustment for covariates, the APOE 2 group had an ap-
proximately 7-point decrease in PDI score. The smaller 2
effect on MDI was not significant after preoperative (P 
.09) or preoperative plus postoperative (P  .13) covariate
adjustment, although the trend of poorer outcome among
the 2 subjects persisted. The effect of APOE 2 on neuro-
muscular examination was no longer significant after pre-
operative (P  .18) or preoperative plus postoperative (P 
.26) covariate adjustment. Head circumference at 1 year did
not have a significant APOE genotype effect with or without
covariate adjustment.
An APOE 4 effect was not seen for any outcome. The
regression coefficients for the covariate-adjusted regression
were near 0 for PDI and MDI. After covariate adjustment,
nonsignificantly negative coefficients were seen for the 4
effect on PDI, MDI, and head circumference.
There was no statistically significant interaction between
the pooled APOE 2 group and presence of a genetic syn-
drome, sex, race, SES, diagnostic group, operative class,
support time, or use of DHCA in the analysis of PDI or
MDI. Power to detect interactions was expected to be low in
this sample size; therefore, the estimated APOE coefficients
specific to covariate strata were examined for consistency.
For prediction of PDI, the coefficients of the pooled group
compared with the 33 reference group were negative for
all strata evaluated, except for diagnostic group 1 (HLHS;
1.2; SD, 7.3) and Hispanic race (13.1; SD, 17.0). The effect
of the 2 group on PDI was 4.1 (SD, 3.9) in subjects with
normal genetic evaluation results and 6.9 (SD, 8.0) in
subjects who were thought to have a genetic disorder. The
2 coefficient for PDI was 1.7 (SD, 5.3) in females and
TABLE 2. Preoperative variables stratified by APOE genotype
Variable
Missing APOE
and 24 22, 23 33 34, 44 All
P value*No. % No. % No. % No. % No. %
Race
Asian/Pacific Islander,
Hispanic, Native
American, other
2 11.7 3 10.7 31 21.1 7 13.5 43 17.6 .308
Black, not hispanic 5 29.4 3 10.7 16 10.9 10 19.2 34 13.9
White, not hispanic 10 58.9 22 78.6 100 68.0 35 67.3 167 68.5
Sex
Female 8 47.1 10 35.7 57 38.8 28 53.8 103 42.2 .130
Male 9 52.9 18 64.3 90 61.2 24 46.2 141 57.8
SES
Groups 1 through 3 4 23.5 13 46.4 41 28.1 19 36.5 77 31.7 .124
Groups 4 and 5 13 76.5 15 53.6 105 71.9 33 63.5 166 68.3
Genetic exclusion
Normal 10 58.9 19 67.9 110 74.8 36 69.2 175 71.7 .759
Abnormal 2 11.7 5 17.9 16 10.9 6 11.6 29 11.9
Unknown 5 29.4 4 14.2 21 14.3 10 19.2 40 16.4
Gestational age (wk)
Mean  SD 38.3 2.3 38.5 2.8 38.4 2.1 39.1 1.8 38.6* 2.1 .151
n 17 28 147 52 244
Birth weight (%)
Mean  SD 48.8 31.0 55.5 31.9 49.2 29.5 59.4 29.4 52.*3 30.0 .091
n 17 28 147 51 243
Birth head circumference (%)
Mean  SD 45.7 30.0 43.1 34.9 41.6 30.9 43.6 29.7 42.2* 31.0 .920
n 15 26 141 49 231
Apgar at 1 min
Mean  SD 8.2 0.7 7.5 1.6 7.7 1.7 7.8 1.7 7.7* 1.6 .665
n 17 27 140 49 233
Apgar at 5 min
Mean  SD 8.9 0.3 8.4 1.0 8.7 1.0 8.7 0.7 8.6* 0.9 .319
n 17 27 140 49 233
*Does not include 24 and missing genotypes.
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10.4 (SD, 4.2) in males. The 2 coefficient for MDI
analysis was negative in all strata except diagnostic group 1
(HLHS; 3.2; SD, 6.6) and class IV patients (1.7; SD, 6.0).
For the analysis of PDI and MDI, there was no signifi-
cant interaction between the APOE 34 and 44 genotype
groups and presence of a genetic syndrome, sex, race, SES,
diagnostic group, operative class, or DHCA. For neuromus-
cular examination, the 2 group generally had worse exam-
ination results across the strata evaluated. A marginally
significant APOE genotype  sex interaction (P  .0581)
was detected in the analysis of neurologic examination.
Only the 2 group males had worse examination results than
the 33 genotype group (1.8; SD, 0.8); the 2 group
coefficient for females was 1.0 (SD, 0.9).
For the prediction of head circumference, a marginal
APOE genotype  genetic diagnosis interaction was de-
tected (P  .0503). The coefficient for the 2 group without
evidence of a genetic disorder was 7.4 (7.2), whereas that
for the 2 group with evidence of a genetic disorder was
20.0 (SD, 14.3). The 4 coefficients without and with evi-
dence of a genetic disorder were 0.05 (SD, 5.5) and 22.9
(SD, 13.6), respectively.
Discussion
There is a significant effect of the APOE 2 allele to predict
lower PDI at 1 year of age after infant cardiac surgery; this
is independent of race, SES, cardiac defect, and use of
DHCA. This finding is consistent with the hypothesis that
APOE genotypes other than the common 33 predict de-
creased neuroresiliency after CNS injury. An APOE 4
effect is not detectable.
TABLE 3. Perioperative variables stratified by APOE genotype: first operation
Variable
Missing APOE
and 24 22, 23 33 34, 44 All P
value*No. % No. % No. % No. % No. %
Operative class
Two ventricles: no arch
obstruction
12 70.6 14 50.0 88 59.9 29 55.8143 58.6 .554
Two ventricles: arch
obstruction
2 11.8 2 7.1 10 6.8 7 13.4 21 8.6
Single ventricle: no
arch obstruction
5 17.9 16 10.9 8 15.4 29 11.9
Single ventricle: arch
obstruction
3 17.6 7 25.0 33 22.4 8 15.4 51 20.9
Diagnostic group
HLHS 2 11.8 6 21.4 22 15.0 5 9.6 35 14.3
Conotruncal defects 10 58.8 14 50.0 80 54.4 31 59.6135 55.3
Other defects 5 29.4 8 28.6 45 30.6 16 30.8 74 30.4 .704
Surgeon
1 5 29.4 3 10.7 36 24.5 12 23.1 56 23.0 .488
2 10 58.8 16 57.2 75 51.0 22 42.3123 50.4
3 1 5.9 3 10.7 15 10.2 9 17.3 28 11.5
4 1 5.9 6 21.4 21 14.3 9 17.3 37 15.1
Age at surgery (d)
Mean  SD 39 50 49 58 42 55 44 52 43* 54 .852
n 17 28 147 52 244
Weight (kg)
Mean  SD 3.63 1.09 3.77 1.37 3.98 1.32 4.10 1.36 3.98* 1.33 .584
n 17 28 147 52 244
Hematocrit on CPB
Mean  SD 27 4 26 3 26 3 26 4 26* 3 .625
n 17 28 147 52 244
Total support time (min)
Mean  SD 90 44 89 47 92 41 99 47 93* 43 .467
n 17 28 147 52 244
Total CPB time (min)
Mean  SD 66 44 65 40 70 44 81 47 72* 44 .217
n 17 28 147 52 244
Total DHCA time (min)
Mean  SD 24 19 24 26 22 23 19 22 21* 23 .580
n 17 28 147 52 244
*Does not include 24 and missing genotypes.
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The gene for the human APOE is located on the long arm
of chromosome 19 and codes for a 299–amino acid pro-
tein.11 The most common allele in humans is 3, and there
are 2 other common alleles, 2 and 4, whose protein
products differ from that of 3 by single amino acid substi-
tutions. There are 3 homozygous genotypes (22, 33,
and 44) and 3 heterozygous genotypes (23, 24, and
34). Allele frequency varies according to ethnic back-
ground.21-27
The APOE protein is the receptor ligand for low-density
lipoprotein cholesterol. APOE-containing lipoproteins are
the primary lipid transport vehicles in the CNS. APOE
modulates lipoprotein levels by effects on clearance rate,
lipolytic conversion, and very-low-density lipoprotein
(VLDL) triglyceride production.11 In addition, APOE has
an important role in mobilization and redistribution of cho-
lesterol and phospholipids during remodeling of neuronal
membranes. The normal function of APOE within neurons
is thought to be maintenance of microtubular integrity and
stabilization of the neuronal cytoskeleton.11 APOE synthe-
sis is upregulated by astrocytes and oligodendrocytes after
CNS injury or cerebral ischemia. After an injury, APOE
immunoreactivity increases first in astrocytes and later in
neurons. The temporal changes in localization and levels of
TABLE 4. Operative data: first year of life
Variable
Missing
APOE and
24 22, 23 33 34, 44 All P
value*No. % No. % No. % No. % No. %
Total number of separate operations with CPB
1 15 88.2 18 64.3 100 68.0 39 75.0 172 70.5 .700
2 2 11.8 10 35.7 42 28.6 13 25.0 67 27.5
3 4 2.7 4 1.6
4 1 0.7 1 0.4
Total number of episodes of CPB
1 12 70.6 17 60.7 95 64.6 37 71.2 161 66.0 .377
2 4 23.5 10 35.7 43 29.3 9 17.3 66 27.0
3 1 5.9 5 3.4 4 7.7 10 4.1
4 1 3.6 4 2.7 2 3.8 7 2.9
Cumulative duration of DHCA (min)
Mean  SD 27 23 31 33 28 33 22 26 27* 31 .366
n 17 28 147 52 244
Single longest episode of DHCA (min)
Mean  SD 23 18 23 23 22 23 19 21 21* 23 .646
n 17 28 147 52 244
Cumulative duration of CPB (min)
Mean  SD 71 44 81 44 92 62 100 59 93* 59 .383
n 17 28 147 52 244
*Does not include 24 and missing genotypes.
TABLE 5. Neurodevelopmental outcomes at 1 year stratified by APOE genotype
Variable
22, 23 33 34, 44 All P
value*No. % No. % No. % No. %
Psychomotor Developmental Index
Mean  SD 67.89 18.28 77.86 17.74 78.17 15.04 76.70* 17.47 .016
n 28 147 52 244
Mental Developmental Index
Mean  SD 83.32 17.43 89.65 14.66 89.58 14.09 88.85* 14.97 .144
n 28 147 52 244
Results of neuromuscular examination
Normal 11 39.3 89 60.5 36 69.2 148 60.7 .032
Abnormal or suspect 17 60.7 58 39.5 16 30.8 96 39.3
Head circumference at testing (%)
Mean  SD 29.93 26.63 36.81 30.83 38.80 28.69 36.41* 29.85 .434
n 28 146 52 243
*Does not include 24 and missing genotypes.
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APOE are consistent with an upregulation of APOE by
astrocytes in response to injury, release into the extracellular
space, and uptake by neurons. APOE immunoreactivity
after global ischemia is localized to vulnerable regions such
as the caudate and CA1 region of the hippocampus. Studies
in APOE knockout mice have shown that APOE deficiency
worsens neuronal injury after cerebral ischemia and com-
promises the blood-brain barrier after CNS injury.9,11,28
Mechanisms by which APOE may modify CNS injury
include protection against oxidative stress, modulation of
the glial response to inflammation, and a direct neurotropic
effect on injured neurons.7,9,29,30
Infants undergoing cardiac surgery are at risk for CNS
injury and adverse neurodevelopmental sequelae that sig-
nificantly diminish the quality of life for these children and
their parents.1-6 The need for early intervention, special
education, and rehabilitative services results in considerable
cost to society. Significant interindividual variation in out-
come exists that cannot be completely explained by previ-
ously reported risk factors.3,5,6 Recent studies suggest that
APOE 4 may be a risk factor for neurocognitive decline
after heart surgery in adults; however, the evidence is not
conclusive.18-20 The mechanisms of CNS injury during
infant cardiac surgery are poorly understood and are
likely different from those in adults.7 Children with CHD
often have congenital CNS anomalies; in addition, many
are hypoxic before and after surgery. Use of DHCA
results in a period of global cerebral ischemia. Mecha-
nisms of CNS injury in infants undergoing cardiac sur-
gery include hypoxia/ischemia, emboli, reactive oxygen
species, and inflammatory microvasculopathy.7 APOE
genotype has been shown to modify the inflammatory
TABLE 6. Outcomes for the white subgroup
Variable
22, 23 33 34, 44 All P
value*No. % No. % No. % No. %
Psychomotor Developmental Index
Mean  SD 65.91 19.13 75.31 16.89 75.89 14.21 74.12* 16.89 .047
n 22 100 35 167
Mental Developmental Index
Mean  SD 82.45 18.96 90.31 14.75 88.91 15.85 88.90* 15.76 .149
n 22 100 35 167
Results of neuromuscular examination
Normal 7 31.8 55 55.0 22 62.9 91 54.5 .065
Not normal 15 68.2 45 45.0 13 37.1 76 45.5
Head circumference at testing (%)
Mean  SD 27.89 26.68 40.54 32.11 38.80 28.43 38.37* 30.73 .217
n 22 99 35 166
*Does not include 24 and missing genotypes.
Figure 1. Mental Developmental Index (MDI) and Psychomotor Development Index (PDI) stratified by apolipopro-
tein E (APOE) genotype. *P  .006 versus other groups pooled, unadjusted for covariates. #P  .041 versus other
groups pooled, unadjusted for covariates. The dashed line represents the expected population mean.
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response to CPB and is a risk factor for postoperative
renal dysfunction.29,31,32
Previous studies have implicated APOE 4 as a risk
factor for recovery after brain injury and for Alzheimer’s
disease.9-13 Few studies have focused on the 2 allele; most
classified patients as 4 positive or 4 negative and did not
assess the 2 allele because of its rarity. APOE 2 has been
shown to adversely influence recovery after ischemic stroke
and cardiac arrest and to increase the risk of intracerebral
hemorrhage.12,14-17 The frequency of all 3 APOE alleles
suggests some balancing selection; certain alleles are better
under some conditions, and other alleles are better under
other conditions.
Although this study provides strong evidence of an ad-
verse effect of the APOE 2 allele on neurodevelopmental
outcome, there are several limitations. Children with CHD
are heterogeneous, and many factors besides the genetic
profile affect outcome. However, the sequential analysis
performed in this study adjusted for both patient and pro-
cedural factors known to affect outcome. Furthermore, no
interaction of APOE genotype with these factors could be
identified. In addition, the APOE 2 allele is rare, and the
possibility that the APOE genotype is a surrogate for some
unidentified factor cannot be excluded. There is evidence
that the APOE alleles are heterogeneous within themselves,
and some variants may be more strongly related to outcome
than others. Full sequencing of the APOE region of 72
African American and European individuals detected many
single nucleotide polymorphisms. These studies suggest
that there is a substructure within the common 2, 3, and 4
alleles.33 In other words, each of these alleles is heteroge-
neous, although primarily in the noncoding regions. Al-
though it is possible that an unidentified subset of the 2
alleles is associated with poor outcome, rather than the
entire 2 group, a direct effect of the coding change is the
most likely cause of an association. The lack of any trend
toward a performance difference among carriers of the 4
allele suggests that a true 4 effect was not missed. Finally,
neurodevelopmental assessment at 1 year of age is not
predictive of long-term outcome. Only further evaluation of
these children at an older age can determine whether APOE
genotype is a risk factor for worse long-term outcome.
In summary, the APOE 2 allele predicts worse neuro-
developmental outcome at 1 year of age after infant repair
of CHD. This APOE genotype-environment interaction
demonstrates that genetic polymorphisms that impair neu-
roresiliency and CNS recovery may explain some of the
interindividual variation in developmental outcome after
surgery for CHD. Further studies, with more reliable and
thorough testing, are necessary as the children reach school
age to determine whether APOE genotype predicts a worse
long-term neurodevelopmental outcome.
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